Stable co-existence of Citrobacter rodentium with a lytic bacteriophage during in vivo murine infection
Published in mBio, 2025
Bacteriophages (phages) are increasingly explored as therapeutic agents against bacterial infections. However, most studies focus on in vitro systems, offering limited insight into the complexity of such dynamics in physiological contexts. Here, we use the mouse-restricted enteric pathogen Citrobacter rodentium (CR), a well-established model for human enteropathogenic and enterohemorrhagic Escherichia coli (EPEC and EHEC) infections, to investigate phage-pathogen interactions in a murine model with a complex microbiota. We isolate and characterize Eifel2, a novel lytic phage infecting CR, and generate anti-phage-specific antibodies that enable the visualization of phage infections in vitro. In a murine model of CR infection, oral administration of Eifel2 led to robust phage replication in the gut without reducing the bacterial burden or infection-associated inflammation, confirming the establishment of a stable co-existence in the gut. Despite the emergence of a sub-population of phage-resistant CR mutants in vivo, they did not undergo clonal expansion, indicating that additional selective pressures impaired their widespread dissemination in the gut. Together, our findings demonstrate that imaging approaches can capture key infection stages in vitro, although in vivo models are essential for capturing the complexity of phage-bacteria interactions. This work highlights the importance of studying phage therapy in host-pathogen contexts that include a normal microbiota and a suitable host environment, where dynamic co-existence rather than eradication may define therapeutic outcomes.
Recommended citation: A. Peters, H. Shareefdeen, J. Sanchez-Garrido, E. J. Cohen, R. Denise, J. L. C. Wong, M. Beeby, C. Hill, G. Frankel, Stable co-existence of Citrobacter rodentium with a lytic bacteriophage during in vivo murine infection. mBio, 2025. https://pubmed.ncbi.nlm.nih.gov/41460104/
